TRIAL DETAIL
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 02/01/2008 |
Age of Trial (yrs) 16.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HSP90 inhibitor |
|||
Strategy: |
Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
120ST103 |
|||
Sponsor: |
Biogen Idec |
|||
Patient Contact: |
Biogen Idec
oncologyclinicaltrials@biogenidec.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
BIIB021 is an oral third-generation Hsp90 inhibitor and is manufactured by Biogen Idec. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
2020 Santa Monica Boulevard Suite 600 |
Santa Monica |
CA |
90404 |
USA |
|
4319 Medical Dr. |
San Antonio |
TX |
78229 |
USA |
|
477 N. El Camino Real |
Encinitas |
CA |
92024 |
USA |